Very possible. Management changes this close to the FDA decision date don’t give investors, including myself a “good feeling”. Perhaps the meeting with FDA highlighted deficiencies in the application. Only a guess on my part. Going to be an interesting five weeks.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.